U.S. markets closed

eFFECTOR Therapeutics, Inc. (EFTR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3527+0.0052 (+1.50%)
At close: 03:27PM EDT
0.3600 +0.01 (+2.07%)
After hours: 07:29PM EDT

eFFECTOR Therapeutics, Inc.

142 North Cedros Avenue
Suite B
Solana Beach, CA 92075
United States
858 925 8215

Full Time Employees15

Key Executives

NameTitlePayExercisedYear Born
Dr. Stephen T. Worland Ph.D.CEO, Pres & Director855.25kN/A1958
Mr. Michael Byrnes M.B.A.Chief Financial Officer623.69kN/A1977
Dr. Douglas Warner M.D.Chief Medical Officer304.4kN/A1972
Dr. Siegfried Reich Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardN/AN/A1960
Dr. Davide Ruggero Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardN/AN/AN/A
Dr. Kevan M. Shokat Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardN/AN/AN/A
Dr. Mayank J. Gandhi M.D.Chief Bus. OfficerN/AN/A1978
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Corporate Governance

eFFECTOR Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.